Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ceo.13371 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vitritis following intravitreal faricimab: a retrospective monocentric analysis.
Graefes Arch Clin Exp Ophthalmol
January 2025
15-20 National Ophthalmologic Center, Paris, France.
Purpose: Intravitreal injections of anti-VEGF agents are considered as safe, with a very low rate of intraocular inflammations (IOI). Faricimab is a novel intravitreal bispecific antibody targeting both VEGF-A and angiopoietin-Tie2 independently. Despite a safe profile in randomized clinical trials, several real-life studies have reported cases of IOI.
View Article and Find Full Text PDFIntravitreal Sustained Release Steroid Implants Are Safe and Effective in Patients With Glaucoma Drainage Devices.
Retina
January 2025
Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Purpose: To describe effects of sustained-release steroid delivery devices on intraocular pressure (IOP) in eyes with glaucoma drainage devices (GDD).
Methods: Retrospective case series of eyes with steroid implants (dexamethasone or fluocinolone acetonide) and prior GDD (Ahmed, Baerveldt) without uveitis. Outcomes included IOP, IOP rise, central foveal thickness (CFT), and IOP medications.
Anterior Segment Optical Coherence Tomography Evaluation of a Dexamethasone Intravitreal Implant in the Crystalline Lens: A Case Report.
Int Med Case Rep J
January 2025
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal.
Purpose: Ozurdex is a dexamethasone intravitreal implant approved for the treatment of macular edema secondary to branch or central retinal vein occlusion, non-infectious uveitis affecting the posterior segment of the eye, and diabetic macular edema.
Patients And Methods: We report a case of an accidental injection of the implant into the crystalline lens, successfully managed by surgery afterwards. The case description is supported by Anterior Segment Optical Coherence Tomography (AS-OCT) images.
Outcomes of intravitreal dexamethasone implant (Ozurdex) in patients with post-surgical macular edema - a real-world scenario.
Int J Retina Vitreous
January 2025
Ophthal - Hospital Especializado, São Paulo, SP, Brazil.
Background: Clinically significant macular edema (CME) is the leading cause of visual loss after ophthalmologic surgery due to the release of inflammatory mediators promoted by the procedures. We aimed to evaluate the outcomes of intravitreal Ozurdex (700 µg dexamethasone) implants as a primary therapeutical option for post-surgical macular edema cases.
Methods: Patients with post-surgical macular edema diagnosed by optical coherence tomography (Cirrus SD-OCT) and treated with Ozudex were selected for the current study.
Risk for Ocular Hypertension With Intravitreal Dexamethasone Implants in Black and White Patients With Diabetic Macular Edema.
J Vitreoretin Dis
January 2025
Georgia Retina, Atlanta, GA, USA.
To compare the effects of intravitreal (IVT) 0.7 mg dexamethasone implants on the intraocular pressure (IOP) in Black patients and White patients with diabetic macular edema (DME). A retrospective cohort study was performed of Black patients and White patients with DME who received dexamethasone implants with 12 or more months of follow-up.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!